Core Insights - The company, Turns Pharmaceuticals, is developing a new drug, Turn 701, for chronic myeloid leukemia (CML) that has shown approximately three times better efficacy than the current standard of care [1][3] - The drug has achieved a 75% major molecular response rate in patients who have undergone two or more prior treatments, indicating significant potential for those with limited options [3] - The company plans to initiate pivotal trials by the end of 2026, aiming to bring the drug to market soon [4] Market Potential - The current leading drug for CML is projected to reach peak sales of $4 billion, and the new drug is expected to have a larger addressable market due to its superior efficacy and the chronic nature of the disease [5][6] - Investors are optimistic about the drug's potential, contributing to a valuation close to $5 billion for the company [5] Development Focus - The company is primarily focused on bringing Turn 701 to market, with plans to share more information about additional assets in the pipeline in the future [6][7]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) experienced a significant stock increase of 53% over the past week, driven by positive results from its therapy candidate for chronic myeloid leukemia (CML) [1][5]. Group 1: Clinical Results - The therapy candidate TERN-701 showed a 64% improvement in the conditions of 63 enrolled patients after 24 weeks of treatment [2]. - A major molecular response rate of 74% was observed at a higher dosage of 320 mg [2]. - Out of the total enrollees, 55 patients continued treatment, while four dropped out due to disease progression [2][3]. Group 2: Market Response - Following the positive clinical results, Terns Pharmaceuticals received a price target increase of 107% to $58 from Oppenheimer, which also assigned an "outperform" rating to the stock [3]. - Oppenheimer highlighted the potential of TERN-701 as a "best-in-class" therapy in the CML market [3]. Group 3: Financial Developments - Terns Pharmaceuticals successfully raised $747.5 million through the issuance of over 18.68 million shares at an offer price of $40 each, including the underwriters' full exercise of their overallotment option covering 2.4 million shares [4][5]. - The funds raised will be allocated for the development and commercial launch of TERN-701, as well as for working capital and other corporate purposes [5].

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

Core Points - Terns Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 18,687,500 shares at a price of $40.00 per share, resulting in gross proceeds of $747.5 million before deductions [1][3] - The offering was managed by Jefferies, TD Cowen, and Leerink Partners as lead book-running managers, with Mizuho, Citizens Capital Markets, and Oppenheimer & Co. as co-managers [2] - The net proceeds from the offering will be utilized for research, clinical trials, development, and manufacturing of key product candidates, particularly TERN-701, as well as for working capital and general corporate purposes [3][5] Company Overview - Terns Pharmaceuticals is a clinical-stage oncology company focused on developing high-impact medicines, with its lead program TERN-701 being a selective allosteric BCR-ABL inhibitor aimed at improving treatment efficacy for chronic myeloid leukemia (CML) [5]

Core Points - Terns Pharmaceuticals, Inc. announced the pricing of its upsized underwritten public offering of 16,250,000 shares at $40.00 per share, aiming for gross proceeds of $650 million [1] - The offering is expected to close on December 11, 2025, subject to customary closing conditions [1] - Terns has granted underwriters a 30-day option to purchase an additional 2,437,500 shares [1] Offering Details - Jefferies, TD Cowen, and Leerink Partners are the lead book-running managers for the offering, with Mizuho, Citizens Capital Markets, and Oppenheimer & Co. as co-managers [2] - A shelf registration statement was filed with the SEC on December 9, 2025, and became effective on the same date [4] Use of Proceeds - The net proceeds from the offering will be used to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, as well as for working capital and general corporate purposes [3][6]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] Group 1: Industry Overview - The biotech, pharma, and healthcare industries are experiencing significant movements, necessitating investors to track developments closely [1] - The Haggerston BioHealth investing group provides insights into catalysts for investment decisions, including buy and sell ratings [1] Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the sector [1] - The investing group led by Ingham caters to both novice and experienced investors, offering forecasts and financial analyses for major pharmaceutical companies [1]

Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] Group 1: Industry Overview - The biotech, pharma, and healthcare industries are experiencing significant movements, necessitating investors to track developments closely [1] - The Haggerston BioHealth investing group provides insights into catalysts for investment decisions, including buy and sell ratings [1] Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience, has compiled detailed reports on more than 1,000 companies in the sector [1] - The investing group led by Ingham caters to both novice and experienced investors, offering forecasts and integrated financial analyses [1]

Core Viewpoint - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) achieved an all-time high stock price following positive clinical trial results for its drug candidate TERN-701, aimed at treating chronic myeloid leukemia (CML) [1][3]. Group 1: Stock Performance - Terns' stock reached a peak price of $45 during intra-day trading, ultimately closing at $40.23, reflecting a 37.02% increase [2]. - The stock received a significant price target upgrade of 107% from Oppenheimer, raising the target from $28 to $58, while maintaining an "outperform" rating [4]. Group 2: Clinical Trial Results - The clinical trial for TERN-701 demonstrated a 64% major molecular response rate (MMR) among 63 enrolled patients after 24 weeks of treatment [3]. - Higher doses of 320 mg resulted in a 74% MMR, indicating a strong efficacy profile for the drug candidate [3]. - Out of the 63 patients, 55 continued treatment, while 8 patients discontinued for various reasons, including disease progression and adverse effects [3][4]. Group 3: Market Implications - The positive trial results suggest a potential "best-in-class profile" for TERN-701 in the CML market, enhancing investor confidence in Terns Pharmaceuticals [4].

Core Insights - Terns Pharmaceuticals presented updated data from the CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) patients, showing promising efficacy and safety results [1][3]. Efficacy Data - Among 38 efficacy-evaluable patients, the overall major molecular response (MMR) rate was 74% (28 out of 38) at 24 weeks, with 64% (18 out of 28) achieving MMR and 100% (10 out of 10) maintaining MMR [2][3]. - The deep molecular response (DMR) achievement rate was 29% by 24 weeks, with no patients losing MMR at the data cutoff [3][5]. - The reported MMR achievement rate of 64% is significantly higher than that of approved treatments like Scemblix and investigational agents, which reported rates of 24%-32% [8]. Safety Profile - The safety profile of TERN-701 was encouraging, with 87% (55 out of 63) of patients remaining on treatment as of the data cutoff [3]. - No dose-limiting toxicities were observed, and a maximum tolerated dose was not reached, indicating a favorable safety profile [3][4]. - The majority of treatment-emergent adverse events were low grade, with no apparent dose relationship [4]. Recommended Doses - The higher MMR achievement rate of 75% at doses of 320mg and above supports the selection of 320mg and 500mg QD as the recommended phase 2 doses for expansion [4][6]. Market Potential - Analysts believe TERN-701 has the potential to disrupt the CML treatment landscape, which has a global total addressable market (TAM) of approximately $5 billion [7]. - The consistency of efficacy data from the trial adds to the bullish sentiment among analysts regarding TERN-701's market prospects [9].